Albany Molecular Research Company Profile (NASDAQ:AMRI)

About Albany Molecular Research (NASDAQ:AMRI)

Albany Molecular Research logoAlbany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AMRI
  • CUSIP: N/A
  • Web: www.amriglobal.com
Capitalization:
  • Market Cap: $782.57 million
  • Outstanding Shares: 41,604,000
Average Prices:
  • 50 Day Moving Avg: $16.53
  • 200 Day Moving Avg: $16.64
  • 52 Week Range: $12.51 - $19.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 13.83
  • P/E Growth: 1.52
Sales & Book Value:
  • Annual Revenue: $628.69 million
  • Price / Sales: 1.24
  • Book Value: $7.13 per share
  • Price / Book: 2.64
Profitability:
  • EBIDTA: $71.8 million
  • Net Margins: -10.48%
  • Return on Equity: 7.25%
  • Return on Assets: 2.26%
Debt:
  • Debt-to-Equity Ratio: 1.79%
  • Current Ratio: 2.21%
  • Quick Ratio: 1.11%
Misc:
  • Average Volume: 772,546 shs.
  • Beta: 1.26
  • Short Ratio: 11.25
 

Frequently Asked Questions for Albany Molecular Research (NASDAQ:AMRI)

What is Albany Molecular Research's stock symbol?

Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."

How were Albany Molecular Research's earnings last quarter?

Albany Molecular Research, Inc. (NASDAQ:AMRI) issued its quarterly earnings results on Tuesday, May, 9th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.12 by $0.01. The firm earned $163.80 million during the quarter, compared to analyst estimates of $161.43 million. Albany Molecular Research had a positive return on equity of 7.25% and a negative net margin of 10.48%. Albany Molecular Research's quarterly revenue was up 55.1% compared to the same quarter last year. During the same period last year, the company earned $0.07 EPS. View Albany Molecular Research's Earnings History.

What guidance has Albany Molecular Research issued on next quarter's earnings?

Albany Molecular Research issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of $1.08-1.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.16. The company issued revenue guidance of $710-740 million, compared to the consensus revenue estimate of $720.68 million.

Where is Albany Molecular Research's stock going? Where will Albany Molecular Research's stock price be in 2017?

2 equities research analysts have issued 12-month price objectives for Albany Molecular Research's shares. Their predictions range from $18.00 to $18.00. On average, they anticipate Albany Molecular Research's share price to reach $18.00 in the next year. View Analyst Ratings for Albany Molecular Research.

Are investors shorting Albany Molecular Research?

Albany Molecular Research saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 6,689,913 shares, an increase of 6.5% from the March 31st total of 6,282,021 shares. Based on an average daily volume of 874,570 shares, the short-interest ratio is presently 7.6 days.

Who are some of Albany Molecular Research's key competitors?

Who owns Albany Molecular Research stock?

Albany Molecular Research's stock is owned by a number of of retail and institutional investors. Top institutional investors include Permian Investment Partners LP (7.51%), Obermeyer Wood Investment Counsel Lllp (0.00%), Royce & Associates LP (0.00%), Dimensional Fund Advisors LP (0.00%), Vanguard Group Inc. (0.00%) and Rice Hall James & Associates LLC (2.96%). Company insiders that own Albany Molecular Research stock include Ambra Constance M D, Anthony J Maddaluna, George Svokos, Kevin Oconnor, Lori M Henderson, Steven R Hagen, Stuart M Cable and William S Marth. View Institutional Ownership Trends for Albany Molecular Research.

Who sold Albany Molecular Research stock? Who is selling Albany Molecular Research stock?

Albany Molecular Research's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Permian Investment Partners LP, AMI Asset Management Corp, Dimensional Fund Advisors LP, Cove Street Capital LLC, Moody Aldrich Partners LLC, Netols Asset Management Inc. and Rice Hall James & Associates LLC. Company insiders that have sold Albany Molecular Research stock in the last year include Kevin Oconnor, Lori M Henderson and Steven R Hagen. View Insider Buying and Selling for Albany Molecular Research.

Who bought Albany Molecular Research stock? Who is buying Albany Molecular Research stock?

Albany Molecular Research's stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Stoneridge Investment Partners LLC, Morgan Stanley, Walthausen & Co. LLC, Vanguard Group Inc., Fisher Asset Management LLC, Dynamic Technology Lab Private Ltd and Bank of America Corp DE. Company insiders that have bought Albany Molecular Research stock in the last two years include Anthony J Maddaluna, George Svokos and William S Marth. View Insider Buying and Selling for Albany Molecular Research.

How do I buy Albany Molecular Research stock?

Shares of Albany Molecular Research can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Albany Molecular Research stock cost?

One share of Albany Molecular Research stock can currently be purchased for approximately $18.81.

Analyst Ratings

Consensus Ratings for Albany Molecular Research (NASDAQ:AMRI) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $18.00 (4.31% downside)

Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017William BlairReiterated RatingOutperformLowView Rating Details
5/11/2017Morgan StanleyDowngradeOverweight -> Equal Weight$18.00HighView Rating Details
10/26/2015First AnalysisUpgradeEqual Weight -> Overweight$25.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Albany Molecular Research (NASDAQ:AMRI)
Earnings by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Earnings History by Quarter for Albany Molecular Research (NASDAQ:AMRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.12$0.13$161.43 million$163.80 millionViewListenView Earnings Details
2/21/2017Q416$0.48$0.34$221.30 million$191.30 millionViewListenView Earnings Details
11/8/2016Q316$0.13$0.17$160.75 million$151.70 millionViewListenView Earnings Details
5/10/2016Q1$0.21$0.07$107.20 million$102.80 millionViewListenView Earnings Details
2/17/2016Q415$0.36$0.40$133.40 million$126.40 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.11$95.15 million$101.40 millionViewListenView Earnings Details
8/4/2015Q215$0.18$0.19$85.00 million$85.20 millionViewListenView Earnings Details
5/5/2015Q115$0.15$0.20$81.50 million$75.10 millionViewN/AView Earnings Details
2/12/2015Q414$0.33$0.28$91.90 million$86.60 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.16($0.02)$71.00 million$62.47 millionViewN/AView Earnings Details
8/5/2014Q214$0.20$0.22$65.64 million$68.20 millionViewN/AView Earnings Details
5/6/2014Q114$0.23$0.16$62.19 million$51.00 millionViewN/AView Earnings Details
2/12/2014Q4$0.17$0.22ViewN/AView Earnings Details
11/6/2013Q313$0.11$0.13$62.10 million$53.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.12$50.00 million$59.30 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.10$0.23$53.70 million$59.40 millionViewN/AView Earnings Details
2/12/2013Q4 2012$0.09$0.17$56.49 million$59.10 millionViewN/AView Earnings Details
8/1/2012$0.02$0.01ViewN/AView Earnings Details
5/9/2012$0.05$0.02ViewN/AView Earnings Details
2/7/2012($0.12)($0.19)ViewN/AView Earnings Details
11/8/2011($0.05)($0.19)ViewN/AView Earnings Details
8/8/2011($0.03)($0.02)ViewN/AView Earnings Details
5/4/2011($0.14)($0.02)ViewN/AView Earnings Details
2/7/2011($0.15)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)
2017 EPS Consensus Estimate: $1.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.11$0.11$0.11
Q2 20172$0.23$0.28$0.26
Q3 20172$0.15$0.19$0.17
Q4 20172$0.42$0.54$0.48
Q1 20181$0.22$0.22$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Albany Molecular Research (NASDAQ:AMRI)
Insider Ownership Percentage: 17.50%
Institutional Ownership Percentage: 72.07%
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Anthony J MaddalunaDirectorBuy1,518$16.46$24,986.28View SEC Filing  
11/30/2016Steven R HagenSVPSell9,000$16.71$150,390.00View SEC Filing  
11/16/2016Lori M HendersonSVPSell6,000$17.00$102,000.00View SEC Filing  
11/10/2016Steven R HagenSVPSell785$16.79$13,180.15View SEC Filing  
8/9/2016Steven R HagenSVPSell1,401$15.29$21,421.29View SEC Filing  
5/31/2016Kevin OconnorDirectorSell5,000$14.41$72,050.00View SEC Filing  
5/16/2016William S MarthCEOBuy12,500$12.86$160,750.00View SEC Filing  
5/13/2016George SvokosCOOBuy12,500$12.82$160,250.00View SEC Filing  
5/13/2016Steven R HagenSVPSell2,361$12.77$30,149.97View SEC Filing  
11/9/2015Ambra Constance M DMajor ShareholderSell50,000$19.60$980,000.00View SEC Filing  
8/17/2015Steven R HagenSVPSell1,000$20.45$20,450.00View SEC Filing  
6/10/2015Ambra Constance M DMajor ShareholderSell20,000$19.77$395,400.00View SEC Filing  
6/8/2015Steven R HagenSVPSell5,000$19.99$99,950.00View SEC Filing  
6/4/2015William S MarthCEOBuy10,000$19.98$199,800.00View SEC Filing  
6/1/2015Stuart M CableMajor ShareholderSell30,000$19.69$590,700.00View SEC Filing  
5/11/2015Ambra Constance M DMajor ShareholderSell20,000$19.11$382,200.00View SEC Filing  
5/8/2015Steven R HagenSVPSell14,500$19.27$279,415.00View SEC Filing  
4/10/2015Ambra Constance M DMajor ShareholderSell20,000$18.50$370,000.00View SEC Filing  
3/17/2015Steven R HagenSVPSell3,500$18.53$64,855.00View SEC Filing  
3/12/2015Kevin OconnorDirectorSell5,000$18.22$91,100.00View SEC Filing  
3/10/2015Ambra Thomas E Phd DDirectorSell20,000$17.65$353,000.00View SEC Filing  
3/10/2015George SvokosInsiderBuy10,000$17.72$177,200.00View SEC Filing  
3/5/2015William S MarthCEOBuy20,000$17.70$354,000.00View SEC Filing  
3/2/2015Stuart M CableMajor ShareholderSell30,000$16.39$491,700.00View SEC Filing  
2/10/2015Ambra Thomas E Phd DDirectorSell20,000$16.91$338,200.00View SEC Filing  
2/2/2015Stuart M CableMajor ShareholderSell30,000$16.32$489,600.00View SEC Filing  
1/12/2015Ambra Thomas E Phd DDirectorSell20,000$16.45$329,000.00View SEC Filing  
1/7/2015Stuart M CableMajor ShareholderSell7,694$16.00$123,104.00View SEC Filing  
1/5/2015Stuart M CableMajor ShareholderSell22,306$16.21$361,580.26View SEC Filing  
12/10/2014Ambra Constance M DMajor ShareholderSell20,000$16.24$324,800.00View SEC Filing  
12/5/2014Stuart M CableMajor ShareholderSell13,307$16.00$212,912.00View SEC Filing  
12/4/2014Stuart M CableMajor ShareholderSell16,693$16.00$267,088.00View SEC Filing  
11/10/2014William S MarthCEOBuy30,000$17.01$510,300.00View SEC Filing  
10/10/2014Ambra Constance M DMajor ShareholderSell20,000$21.62$432,400.00View SEC Filing  
10/1/2014Lori M HendersonSVPSell1,000$21.48$21,480.00View SEC Filing  
10/1/2014Stuart M CableMajor ShareholderSell30,000$21.61$648,300.00View SEC Filing  
9/10/2014Ambra Constance M DMajor ShareholderSell20,000$20.12$402,400.00View SEC Filing  
9/2/2014Lori M HendersonSVPSell2,500$19.56$48,900.00View SEC Filing  
8/28/2014Steven R HagenSVPSell1,250$19.74$24,675.00View SEC Filing  
8/14/2014Michael M NolanCFOSell10,000$19.76$197,600.00View SEC Filing  
8/12/2014Lori M HendersonSVPSell30,000$19.05$571,500.00View SEC Filing  
8/11/2014Ambra Thomas E Phd DDirectorSell20,000$18.99$379,800.00View SEC Filing  
8/8/2014Steven R HagenSVPSell10,797$18.99$205,035.03View SEC Filing  
8/1/2014Lori M HendersonSVPSell2,500$18.56$46,400.00View SEC Filing  
8/1/2014Stuart M CableMajor ShareholderSell30,000$18.69$560,700.00View SEC Filing  
7/10/2014Ambra Thomas E Phd DDirectorSell20,000$20.94$418,800.00View SEC Filing  
7/1/2014Lori M HendersonSVPSell2,500$20.62$51,550.00View SEC Filing  
7/1/2014Stuart M CableMajor ShareholderSell30,000$21.00$630,000.00View SEC Filing  
6/3/2014Steven R HagenSVPSell2,500$16.93$42,325.00View SEC Filing  
5/16/2014Steven HagenSVPSell1,250$15.45$19,312.50View SEC Filing  
5/15/2014George SvokosSVPBuy10,000$15.60$156,000.00View SEC Filing  
5/12/2014Steven HagenSVPSell5,897$15.00$88,455.00View SEC Filing  
5/12/2014William MarthCEOBuy30,000$15.40$462,000.00View SEC Filing  
5/1/2014Lori HendersonVPSell2,500$15.73$39,325.00View SEC Filing  
5/1/2014Stuart Cablemajor shareholderSell30,000$15.98$479,400.00View SEC Filing  
4/1/2014Lori HendersonVPSell2,500$18.74$46,850.00View SEC Filing  
4/1/2014Stuart Cablemajor shareholderSell30,000$18.52$555,600.00View SEC Filing  
2/27/2014Arthur RothDirectorSell5,000$15.95$79,750.00View SEC Filing  
2/27/2014Steven HagenSVPSell3,000$15.73$47,190.00View SEC Filing  
2/25/2014Steven HagenSVPSell2,500$15.19$37,975.00View SEC Filing  
2/24/2014Michael NolanCFOSell15,000$15.00$225,000.00View SEC Filing  
2/21/2014Steven HagenSVPSell1,500$14.87$22,305.00View SEC Filing  
2/19/2014Steven HagenSVPSell1,500$13.37$20,055.00View SEC Filing  
2/13/2014Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
12/4/2013Steven HagenSVPSell2,500$10.93$27,325.00View SEC Filing  
12/3/2013William MarthDirectorBuy30,000$10.75$322,500.00View SEC Filing  
11/22/2013Steven HagenSVPSell2,300$11.55$26,565.00View SEC Filing  
11/22/2013William MarthDirectorBuy20,000$11.57$231,400.00View SEC Filing  
9/13/2013Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
8/1/2013Stuart M CableMajor ShareholderSell30,000$12.53$375,900.00View SEC Filing  
7/1/2013Stuart M CableMajor ShareholderSell30,000$12.47$374,100.00View SEC Filing  
6/12/2013Stuart M CableMajor ShareholderSell30,000$12.00$360,000.00View SEC Filing  
5/22/2013Bruce J SargentSVPSell7,500$10.97$82,275.00View SEC Filing  
5/10/2013Steven R HagenSVPSell1,200$10.40$12,480.00View SEC Filing  
12/3/2012William S MarthDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/15/2012Ambra Thomas E Phd DCEOBuy10,000$3.80$38,000.00View SEC Filing  
8/9/2012Steven R HagenVPSell3,000$3.00$9,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Albany Molecular Research (NASDAQ:AMRI)
Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)
Source:
DateHeadline
americanbankingnews.com logoEquities Analysts Issue Forecasts for Albany Molecular Research, Inc.'s Q2 2017 Earnings (AMRI)
www.americanbankingnews.com - May 26 at 8:02 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Receives "Outperform" Rating from William Blair
www.americanbankingnews.com - May 23 at 11:48 PM
americanbankingnews.com logoFirst Analysis Analysts Cut Earnings Estimates for Albany Molecular Research, Inc. (AMRI)
www.americanbankingnews.com - May 17 at 8:08 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Forecasted to Earn Q3 2017 Earnings of $0.19 Per Share
www.americanbankingnews.com - May 16 at 8:18 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Cut to "Equal Weight" at Morgan Stanley
www.americanbankingnews.com - May 13 at 11:56 PM
streetinsider.com logoMorgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to Equalweight
www.streetinsider.com - May 11 at 3:53 PM
streetinsider.com logoMorgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to Equalweight
www.streetinsider.com - May 11 at 3:53 PM
seekingalpha.com logoAlbany Molecular Research, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 10 at 3:43 PM
finance.yahoo.com logoEdited Transcript of AMRI earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 9:21 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Issues FY17 Earnings Guidance
www.americanbankingnews.com - May 9 at 2:24 PM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 9 at 11:24 AM
finance.yahoo.com logoAMRI Announces First Quarter 2017 Results
finance.yahoo.com - May 9 at 9:00 AM
finance.yahoo.com logoInvestor Network: Albany Molecular Research, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 9:00 AM
marketbeat.com logoAlbany Molecular Research posts 1Q loss
marketbeat.com - May 9 at 8:43 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:04 AM
americanbankingnews.com logoAlbany Molecular Research (AMRI) Given News Sentiment Score of 0.06
www.americanbankingnews.com - May 4 at 3:54 PM
bizjournals.com logoAMRI will bring work from newly awarded federal grant to Buffalo, where it will soon have 40 employees
www.bizjournals.com - May 2 at 3:36 PM
reuters.com logoBRIEF-Albany Molecular Research says AMRI receives NIH contract award
www.reuters.com - May 2 at 3:36 PM
finance.yahoo.com logoAMRI Receives NIH Contract Award for Drug Substance Development and Manufacturing Services
finance.yahoo.com - May 2 at 3:36 PM
americanbankingnews.com logoPositive Press Coverage Somewhat Likely to Impact Albany Molecular Research (AMRI) Share Price
www.americanbankingnews.com - May 1 at 11:46 AM
americanbankingnews.com logoShort Interest in Albany Molecular Research, Inc. (AMRI) Increases By 6.5%
www.americanbankingnews.com - May 1 at 8:52 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Unlikely to Impact Albany Molecular Research (AMRI) Share Price
www.americanbankingnews.com - April 27 at 2:38 PM
finance.yahoo.com logoReport: AMRI considering $1 billion sale
finance.yahoo.com - April 26 at 3:43 PM
finance.yahoo.com logoSSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing
finance.yahoo.com - April 26 at 8:17 AM
finance.yahoo.com logoAMRI Schedules First Quarter 2017 Earnings Release and Conference Call
finance.yahoo.com - April 25 at 9:11 AM
streetinsider.com logoDenovo Biopharma Obtains Exclusive License to Liafensine from Albany Molecular Research (AMRI)
www.streetinsider.com - April 24 at 10:42 AM
finance.yahoo.com logoDenovo Biopharma Obtains Exclusive License To Liafensine From AMRI
finance.yahoo.com - April 24 at 10:42 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Somewhat Unlikely to Impact Albany Molecular Research (AMRI) Share Price
www.americanbankingnews.com - April 20 at 12:49 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Impact Albany Molecular Research (AMRI) Stock Price
www.americanbankingnews.com - April 14 at 4:34 PM
finance.yahoo.com logoETFs with exposure to Albany Molecular Research, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:34 PM
americanbankingnews.com logoFirst Analysis Comments on Albany Molecular Research, Inc.'s Q2 2017 Earnings (AMRI)
www.americanbankingnews.com - March 30 at 9:10 AM
americanbankingnews.com logoAlbany Molecular Research, Inc. (AMRI) to Post Q1 2017 Earnings of $0.11 Per Share, First Analysis Forecasts
www.americanbankingnews.com - March 29 at 11:32 AM
finance.yahoo.com logoAMRI Receives CMO Leadership Awards for Excellence
finance.yahoo.com - March 22 at 4:02 PM
reuters.com logoBRIEF-Albany Molecular Research files for secondary offering of 2.2 mln shares
www.reuters.com - March 17 at 4:13 PM
biz.yahoo.com logoALBANY MOLECULAR RESEARCH INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 5:01 PM
finance.yahoo.com logoAMRI to Present at Barclays Global Healthcare Conference
finance.yahoo.com - March 3 at 3:44 PM
bizjournals.com logoAMRI boosts revenue by 42 percent
www.bizjournals.com - February 23 at 8:34 PM
seekingalpha.com logoAlbany Molecular Research, Inc. 2016 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 22 at 8:32 PM
reuters.com logoBRIEF-Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord Healthcare
www.reuters.com - February 22 at 8:32 PM
investopedia.com logoAlbany Molecular Research 4Q Misses Street (AMRI)
www.investopedia.com - February 22 at 8:32 PM
finance.yahoo.com logoEdited Transcript of AMRI earnings conference call or presentation 21-Feb-17 1:30pm GMT
finance.yahoo.com - February 22 at 11:32 AM
biz.yahoo.com logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors
biz.yahoo.com - February 22 at 11:32 AM
investopedia.com logoAlbany Molecular Research 4Q Net Misses Street
www.investopedia.com - February 22 at 11:32 AM
us.rd.yahoo.com logoAMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook
us.rd.yahoo.com - February 21 at 3:47 PM
us.rd.yahoo.com logoAMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products
us.rd.yahoo.com - February 21 at 3:47 PM
biz.yahoo.com logoQ4 2016 Albany Molecular Research Inc Earnings Release - Before Market Open
biz.yahoo.com - February 21 at 7:27 AM
us.rd.yahoo.com logoAMRI Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call
us.rd.yahoo.com - February 16 at 8:24 AM
streetinsider.com logoSSCI Launches Enhanced Web Site – Improves Customer Online Support Services
www.streetinsider.com - February 8 at 3:45 PM
bizjournals.com logoA high through put mass spectrometer is coming to Buffalo
www.bizjournals.com - February 8 at 3:45 PM
us.rd.yahoo.com logoAMRI Announces Strategic Alliance to Advance Mass Spectrometry Capabilities for Drug Discovery
us.rd.yahoo.com - February 7 at 4:00 PM

Social

Chart

Albany Molecular Research (AMRI) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff